PDE3 inhibition in dilated cardiomyopathy: reasons to reconsider (Q35668903)

9 August 2017

1 reference

title

PDE3 inhibition in dilated cardiomyopathy: reasons to reconsider (English)

1 reference

9 August 2017

dilated cardiomyopathy

1 reference

Matthew A Movsesian

1

1 reference

9 August 2017

1 December 2003

1 reference

Journal of Cardiac Failure

9 August 2017

1 reference

9 August 2017

9

1 reference

9 August 2017

6

1 reference

9 August 2017

475-480

1 reference

Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family

9 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2803%2900135-0

7 January 2021

Beta-adrenergic receptor agonists and cyclic nucleotide phosphodiesterase inhibitors: shifting the focus from inotropy to cyclic adenosine monophosphate

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2803%2900135-0

7 January 2021

Phospholamban: protein structure, mechanism of action, and role in cardiac function

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2803%2900135-0

7 January 2021

Nature and site of phospholamban regulation of the Ca2+ pump of sarcoplasmic reticulum

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2803%2900135-0

7 January 2021

Phosphorylation of the cardiac ryanodine receptor by cAMP-dependent protein kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2803%2900135-0

7 January 2021

Voltage-dependent potentiation of the activity of cardiac L-type calcium channel alpha 1 subunits due to phosphorylation by cAMP-dependent protein kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2803%2900135-0

7 January 2021

Hemodynamic assessment of amrinone. A new inotropic agent

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2803%2900135-0

7 January 2021

Evaluation of a new bipyridine inotropic agent--milrinone--in patients with severe congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2803%2900135-0

7 January 2021

Long-term therapy with a new cardiotonic agent, WIN 47203: drug-dependent improvement in cardiac performance and progression of the underlying disease

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2803%2900135-0

7 January 2021

The acute hemodynamic effects of a new agent, MDL 17,043, in the treatment of congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2803%2900135-0

7 January 2021

Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2803%2900135-0

7 January 2021

Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2803%2900135-0

7 January 2021

Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2803%2900135-0

7 January 2021

A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2803%2900135-0

7 January 2021

Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2803%2900135-0

7 January 2021

Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2803%2900135-0

7 January 2021

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2803%2900135-0

7 January 2021

Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2803%2900135-0

7 January 2021

Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2803%2900135-0

7 January 2021

Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2803%2900135-0

7 January 2021

Effect of carvedilol on survival in severe chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2803%2900135-0

7 January 2021

Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2803%2900135-0

7 January 2021

Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2803%2900135-0

7 January 2021

Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2803%2900135-0

7 January 2021

Carvedilol titration in patients with congestive heart failure receiving inotropic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2803%2900135-0

7 January 2021

Novel use of a short-acting intravenous beta blocker in combination with inotropic therapy as a bridge to chronic oral beta blockade in patients with advanced heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2803%2900135-0

7 January 2021

Effectiveness of carvedilol alone versus carvedilol + pimobendan for severe congestive heart failure. For the Keio Interhospital Cardiology Study (KICS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2803%2900135-0

7 January 2021

Differential regulation of inotropy and lusitropy in overexpressed Gsalpha myocytes through cAMP and Ca2+ channel pathways

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2803%2900135-0

7 January 2021

Coupling of beta-adrenergic receptors to cardiac L-type Ca2+ channels: preferential coupling of the beta1 versus beta2 receptor subtype and evidence for PKA-independent activation of the channel.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2803%2900135-0

7 January 2021

Localization of cardiac sodium channels in caveolin-rich membrane domains: regulation of sodium current amplitude

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2803%2900135-0

7 January 2021

Hypertrophic effect of selective beta(1)-adrenoceptor stimulation on ventricular cardiomyocytes from adult rat

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2803%2900135-0

7 January 2021

Beta 1-adrenoceptor stimulation and beta 2-adrenoceptor stimulation differ in their effects on contraction, cytosolic Ca2+, and Ca2+ current in single rat ventricular cells

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2803%2900135-0

7 January 2021

Differential targeting of beta -adrenergic receptor subtypes and adenylyl cyclase to cardiomyocyte caveolae. A mechanism to functionally regulate the cAMP signaling pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2803%2900135-0

7 January 2021

G(i) protein-mediated functional compartmentalization of cardiac beta(2)-adrenergic signaling

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2803%2900135-0

7 January 2021

cAMP compartmentation is responsible for a local activation of cardiac Ca2+ channels by beta-adrenergic agonists

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2803%2900135-0

7 January 2021

Discrete microdomains with high concentration of cAMP in stimulated rat neonatal cardiac myocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2803%2900135-0

7 January 2021

Inotropic responses to isoproterenol and phosphodiesterase inhibitors in intact guinea pig hearts: comparison of cyclic AMP levels and phosphorylation of sarcoplasmic reticulum and myofibrillar proteins.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2803%2900135-0

7 January 2021

Isoforms of cyclic nucleotide phosphodiesterase PDE3A in cardiac myocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2803%2900135-0

7 January 2021

Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: differential subcellular localization and regulated expression by cyclic AMP

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2803%2900135-0

7 January 2021

10.1016/S1071-9164(03)00135-0

Identifiers

DOI

1 reference

9 August 2017

1 reference

PubMed ID

14966789